TNF and inflammatory bowel disease: As anti-TNF and anti-IL-12/23 treated patients with IBD had broadly similar T cell responses to SARS-CoV-2 vaccination, but differed in their humoral responses, the anti-IL-12/23–treated patients with IBD along with healthy donors served as controls to assess the impact of anti-TNF on GC outputs to vaccination (8, 9).